Skip to main content
Clinical Trials/NCT07283068
NCT07283068
Not yet recruiting
Not Applicable

Intraosseous (IO) Vancomycin Into the Medial Malleolus vs Intravenous (IV) Administration in Revision Total Knee Arthroplasty (TKA)

The Methodist Hospital Research Institute0 sites40 target enrollmentStarted: June 15, 2026Last updated:

Overview

Phase
Not Applicable
Status
Not yet recruiting
Enrollment
40
Primary Endpoint
Level of Vancomycin

Overview

Brief Summary

Purpose of this study is to compare the efficacy of intravenous and intraosseous antibiotic administration techniques during revision total knee arthroplasty

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Prevention
Masking
Single (Participant)

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Patient is undergoing a revision total knee arthroplasty where in the opinion of the investigator, the patient's existing tibial component excludes the tibial tubercle as a valid intraosseous injection site.
  • Patient is able to understand the study design and intervention and gives informed consent to participate in the study.
  • Age \> 18 years.

Exclusion Criteria

  • Contraindication to receiving vancomycin, cefepime, ancef, or other standard of care pre-operative antibiotic (allergy, medical issue, etc).
  • Patient received or is scheduled to receive intravenous Vancomycin within 7 days prior to their planned revision procedure.
  • Any hardware, condition, or anatomic status that prevents the medial malleolus from being a viable intraosseous injection site.
  • Refusal to participate
  • Any condition, in the opinion of the primary investigator, that deems the participant unsuitable for participation in the research study.

Arms & Interventions

Intraosseous (IO) Vancomycin

Experimental

IO vancomycin is administered via an intraosseous cannulation device (Arrow EZ-IO; Teleflex, Morrisville, NC) in the operating room after sterile preparation of the leg and draping has occurred prior to skin incision (500mg in approximately 100mL NS). Injection will take place into the medial malleolus (within a pre-specified region) immediately prior to incision.

Intervention: Intraosseous Vancomycin (Drug)

Intravenous (IV) Vancomycin

No Intervention

Patients will receive the Houston Methodist Hospital orthopedic surgery standard of care pre-operative antibiotic regimen for revision total knee arthroplasty patients. This includes IV antibiotics (typically ancef or cefepime and vancomycin) will be started in the pre-operative period approximately 1 hour prior to incision (vancomycin dose weight based at approximately 15mg/kg [12,13] generally 1000-1750mg in 500mL NS).

Outcomes

Primary Outcomes

Level of Vancomycin

Time Frame: During the surgery

The study team will assess the level of vancomycin in the distal femur, proximal tibia, and systemic samples between the intravenous and intraosseous administration groups.

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Kwan Park, MD

Orthopedic Surgeon

The Methodist Hospital Research Institute

Similar Trials